Clinical trial of new dyskinesia drug starts in Sweden Date 30 November 2021 The first participant has been recruited to a pioneering clinical trial which is testing a new drug called NLX-112 to investigate its potential for people with Parkinson’s.
Working together to put patients at the heart of Parkinson's research Date 26 November 2021 UCB, a global pharmaceutical company, has joined forces with Parkinson's UK, and the Parkinson's Foundation in the US, to establish a Patient Engagement Council for Parkinson's Research.
Launch of a new toolkit for researchers Date 2 November 2021 We’ve developed an interactive communications toolkit to help researchers in all areas of health research to keep in touch with their participants. It is supported by the Health Research Authority (HRA) as part of the Make It Public strategy.
ADHD drug shows promise for improving cognition in Parkinson’s Date 17 August 2021 Results show that atomoxetine, a drug used to treat attention deficit hyperactivity disorder (ADHD), could improve thinking and impulsiveness in Parkinson’s.
Compound found in fruit shows promise for Parkinson’s Date 29 July 2021 Researchers in the United States have shown that a compound found in fruit - farnesol - has the potential to play a protective role to dopamine-producing brain cells.
Controlling protein production in brain cells could help treat Parkinson’s Date 19 May 2021 New research has been published that sheds an important light on how the production of a key protein in the brain is controlled This could pave the way for new treatments for a wide range of neurological conditions.
Scientists move closer to developing ‘game-changing’ test to diagnose Parkinson’s Date 10 March 2021 Research shows it’s possible to identify Parkinson’s based on compounds found on the surface of skin. The findings offer hope that the condition could be diagnosed through a simple swab test.
We're investing £1.2m into drug that could slow Parkinson's Date 9 March 2021 We’re investing up to £1.2m into pioneering research in partnership with the University of Sheffield, which aims to develop a drug to protect dopamine-producing brain cells.
Caption Christine Proctor - participant in the GDNF trial Why we’re committing £800,000 to plan a new GDNF trial Date 23 February 2021 The earlier groundbreaking clinical trial proved inconclusive. So we’re launching a new company tasked with planning a possible new trial.
Further clues about alpha-synuclein Date 11 February 2021 New research has advanced our understanding of a protein called alpha-synuclein, which is believed to play a central role in damaging brain cells in Parkinson’s.
